http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Mo 화학기상증착에 있어서 불순물 농도에 미치는 증착조건의 영향
배상석,서성교,홍은식,김승모,조미정,한혜정,이두성,김세훈,민석홍 국립7개대학공동논문집간행위원회 2001 공업기술연구 Vol.1 No.-
The thermal decomposition process of Mo(CO)_6 on chemical vapor deposition was investigated by analyzing the effects of deposition temperature, pressure, and reaction gas on the phase change of deposited films. Mo_2C was deposited at or below 350℃ due to the incompleteness of thermal decomposition of Mo(CO)_6, but Mo films was successfully deposited at 400℃ or higher temperatures. The variation of deposition pressure did not change the dependence of decomposition process on deposition temperature. The activation energy of surface reaction was 5.8 ㎉/mole.
Prediction of the Shelf-Life of Chilled Foods at Various Temperatures
( Sae Rom Park ),( Yu Si Lee ),( Ji Hyoung Ha ),( Ki Hwan Park ),( Sook Yeon Lee ),( Youn Ju Choi ),( Dong Ho Lee ),( Sun Hee Park ),( Kyung Ryu ),( Hyoung Soo Shin ),( Dong Ho Bae ),( Ae Jung Kim ),( 한국응용생명화학회 2008 Applied Biological Chemistry (Appl Biol Chem) Vol.51 No.4
Bae, Jeong Mo,Kim, Jung Ho,Kwak, Yoonjin,Lee, Dae-Won,Cha, Yongjun,Wen, Xianyu,Lee, Tae Hun,Cho, Nam-Yun,Jeong, Seung-Yong,Park, Kyu Joo,Han, Sae Won,Lee, Hye Seung,Kim, Tae-You,Kang, Gyeong Hoon Nature Publishing Group 2017 The British journal of cancer Vol.116 No.8
<P><B>Background:</B></P><P>Colorectal cancer (CRC) is a heterogeneous disease in terms of molecular carcinogenic pathways. Based on recent findings regarding the multiple serrated neoplasia pathway, we revised an eight-marker panel for a new CIMP classification system.</P><P><B>Methods:</B></P><P>1370 patients who received surgical resection for CRCs were classified into three CIMP subtypes (CIMP-N: 0–4 methylated markers, CIMP-P1: 5–6 methylated markers and CIMP-P2: 7–8 methylated markers). Our findings were validated in a separate set of high-risk stage II or stage III CRCs receiving adjuvant fluoropyrimidine plus oxaliplatin (<I>n</I>=950).</P><P><B>Results:</B></P><P>A total of 1287/62/21 CRCs cases were classified as CIMP-N/CIMP-P1/CIMP-P2, respectively. CIMP-N showed male predominance, distal location, lower T, N category and devoid of <I>BRAF</I> mutation, microsatellite instability (MSI) and <I>MLH1</I> methylation. CIMP-P1 showed female predominance, proximal location, advanced TNM stage, mild decrease of CK20 and CDX2 expression, mild increase of CK7 expression, <I>BRAF</I> mutation, MSI and <I>MLH1</I> methylation. CIMP-P2 showed older age, female predominance, proximal location, advanced T category, markedly reduced CK20 and CDX2 expression, rare <I>KRAS</I> mutation, high frequency of CK7 expression, <I>BRAF</I> mutation, MSI and <I>MLH1</I> methylation. CIMP-N showed better 5-year cancer-specific survival (CSS; HR=0.47; 95% CI: 0.28–0.78) in discovery set and better 5-year relapse-free survival (RFS; HR=0.50; 95% CI: 0.29–0.88) in validation set compared with CIMP-P1. CIMP-P2 showed marginally better 5-year CSS (HR=0.28, 95% CI: 0.07–1.22) in discovery set and marginally better 5-year RFS (HR=0.21, 95% CI: 0.05–0.92) in validation set compared with CIMP-P1.</P><P><B>Conclusions:</B></P><P>CIMP subtypes classified using our revised system showed different clinical outcomes, demonstrating the heterogeneity of multiple serrated precursors of CIMP-positive CRCs.</P>
Lee, Sae-Won,Jeong, Han-Kyul,Lee, Ji-Young,Yang, Jimin,Lee, Eun Ju,Kim, Su-Yeon,Youn, Seock-Won,Lee, Jaewon,Kim, Woo Jean,Kim, Kyu-Won,Lim, Jeong Mook,Park, Jong-Wan,Park, Young-Bae,Kim, Hyo-Soo WILEY-VCH Verlag 2012 EMBO molecular medicine Vol.4 No.9
<P>Hypoxic microenvironment plays an important role in determining stem cell fates. However, it is controversial to which direction between self-renewal and differentiation the hypoxia drives the stem cells. Here, we investigated whether a short exposure to hypoxia (termed ‘hypoxic-priming’) efficiently directed and promoted mouse embryonic stem cells (mESCs) to differentiate into vascular-lineage. During spontaneous differentiation of embryoid bodies (EBs), hypoxic region was observed inside EB spheroids even under normoxic conditions. Indeed, hypoxia-primed EBs more efficiently differentiated into cells of vascular-lineage, than normoxic EBs did. We found that hypoxia suppressed Oct4 expression via direct binding of HIF-1 to reverse hypoxia-responsive elements (rHREs) in the Oct4 promoter. Furthermore, vascular endothelial growth factor (VEGF) was highly upregulated in hypoxia-primed EBs, which differentiated towards endothelial cells in the absence of exogenous VEGF. Interestingly, this differentiation was abolished by the HIF-1 or VEGF blocking. <I>In vivo</I> transplantation of hypoxia-primed EBs into mice ischemic limb elicited enhanced vessel differentiation. Collectively, our findings identify that hypoxia enhanced ESC differentiation by HIF-1-mediated inverse regulation of Oct4 and VEGF, which is a novel pathway to promote vascular-lineage differentiation.</P>
Prediction of the Shelf-life of Chilled Foods at Various Temperatures
Park, Sae-Rom,Lee, Yu-Si,Ha, Ji-Hyoung,Park, Ki-Hwan,Lee, Sook-Yeon,Choi, Youn-Ju,Lee, Dong-Ho,Park, Sun-Hee,Ryu, Kyung,Shin, Hyoung-Soo,Bae, Dong-Ho,Kim, Ae-Jung,Ha, Sang-Do The Korean Society for Applied Biological Chemistr 2008 Applied Biological Chemistry (Appl Biol Chem) Vol.53 No.4
This study was designed to estimate the shelf-life of the popular chilled foods kimbab (rice rolled in dried laver), samgak kimbab (triangular rice rolled in dried laver), eomook (fish surimi, boiled fish paste) mook (acorn-starch jelly), and tofu (soybean curd) in large discount markets and convenience stores. Different types of chilled foods were stored at 5, 7, and 10 for 7 and 28 days, and changes in the total numbers of the aerobic bacteria were monitored. Values of 6 and 7 log cfu/g were used as the standard. Ready-to-eat foods stored at 5 showed a much longer shelf-life compared to storage at 10. The respective percentage increases in the shelf-life observed at both 7 and 5 were kimbab (70%, 171%), samgak kimbab (87%, 143%), soybean curd (46%, 95%), fish surimi (46%, 99%), and mook (45%, 87%). To reduce the microbiological contamination, storages at 7 and 5 are recommended for the increases of 45-88 and 87-171% in the shelf-life of these chilled foods.
Efficacy of Daclatasvir + Asunaprevir for Patients with Chronic HCV Genotype Ib Infection
( Suk Bae Kim ),( Sae Hwan Lee ),( Tae Hee Lee ),( Byung Seok Lee ),( Hee Bok Chae ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated high SVR and low adverse event rate in clinical studies. The purpose of this study is to clarify the results of treatment and side effects in Korean patients. Methods: We retrospectively analyzed the clinical data of chronic HCV genotype Ib patients who treated with DCV (60mg QD) + ASV (100mg BID) between August 2015 and April 2016 at 5 hospitals. The rate of resistant associated variants (RAV), SVR12, adverse events were assessed. Results: Total 152 patients (male; 62, female; 90) got the examination for RAV. Among them, 15 patients (9.9%) showed positivity in Y93 and 1 patient (0.7%) showed positivity in L31. 126 patients (male; 52, female; 74) were treated with DCV + ASV and 8 patients (6.3%) was positive in Y93. 35 patients (27.8%) had cirrhotic change. This treatment was first therapy to 95 patients (75.4%). 20 patients (12.7%) and 15 patients (11.9%) was relapsed after previous treatment including interferon and intolerant to interferon, respectively. Adverse events such as liver enzyme elevation (2), GI discomfort (4), itching or skin rash (4), generalized weakness (2) were found on 10 patients (7.9%). 2 patients stopped the medication because of severe itching sensation and skin rash. Total 59 patients finished the 6 months treatment and 4 patients (6.8%) showed treatment failure. Among 4 patients, 1 relapsed and 1 Y93 positive patient was included. 38 patients who visited at 3 months after treatment showed all SVR12. Conclusions: DCV + ASV treatment revealed good treatment efficacy in patients with chronic hepatitis C in Korea. But close monitoring was needed for severe adverse event and treatment failure although they were found in a few patients.
Byung Seok Lee,Myeong Jun Song,Jung Hyun Kwon,Tae Hee Lee,Ji Woong Jang,Seok Hyun Kim,Sae Hwan Lee,Hong Soo Kim,Ji Hoon Kim,Seok Bae Kim,Soon Young Ko,Do Seon Song 거트앤리버 소화기연관학회협의회 2019 Gut and Liver Vol.13 No.2
Background/Aims: We evaluated the efficacy and safety of daclatasvir (DCV) and asunaprevir (ASV) in patients with chronic hepatitis C virus (HCV) infection on hemodialysis. Methods: We performed a single-arm, multicenter prospective study. Twenty-one chronic hemodialysis patients with HCV infection were prospectively enrolled from February 2016 to April 2017. We evaluated the virological responses at weeks 4, 12, and 24 (end of treatment [EOT]) and the sustained virological response at 12 weeks after the EOT (SVR12). The tolerability and safety of the drugs were also assessed. Results: None of the 20 patients had the NS5A resistance-associated variant (NS5A RAV), and one patient was indeterminate for the NS5A RAV. Seventeen patients (80%) completed the 24 weeks of treatment with DCV and ASV. Four patients discontinued the study prior to week 12. In an intention-to-treat analysis, the SVR12 was 76.1%. In a per-protocol analysis, patients who completed DCV and ASV treatment achieved an SVR12 of 100%. DCV and ASV were well tolerated by the majority of patients. Three patients discontinued treatment due to adverse events (AEs) including dizziness, dyspnea, and neutropenia. The patient with indeterminate NS5A RAV showed viral breakthrough and discontinued treatment. Conclusions: DCV and ASV combination therapy in chronic hemodialysis patients with HCV infection achieved a high SVR12 rate with few AEs. To maximize the SVR12 rate, it is important to identify candidates by baseline RAV testing. Close monitoring of the safety and tolerability of DCV and ASV may be necessary in HCV-infected patients on hemodialysis. (ClinicalTrials.gov ID NCT02580474)